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Abstract: Objectives: Blacks in the United States bear a disproportionate burden of Human Immunodeficiency Virus 
(HIV)/Acquired Immunodeficiency Syndrome (AIDS) and cardiovascular disease (CVD). It has been demonstrated that 
HIV/AIDS itself and HIV/AIDS-related therapies may predispose patients to early onset of CVD. It is also possible that 
Black patients may be at greater risk for this interaction. Thus, the objective of this literature review was to identify and 
critically evaluate disparities in CVD between Black and White patients with HIV/AIDS. 
Design: A MEDLINE search (January 1, 1950 to May 31, 2010) was performed to identify original research articles 
published in the English language. The search was limited to articles that evaluated race-based disparities for CVD among 
patients with HIV/AIDS. 
Results: Of the five publications included in this review, a CVD diagnosis was the primary focus for only three of the 
studies and was a secondary objective for the remaining two studies. Two studies concluded that Blacks were more likely 
than Whites to have a CVD diagnosis at time of hospital admission, whereas, the other three studies did not detect any 
race-based disparities. 
Conclusions: Few studies have addressed the issue of Black race, HIV/AIDS, and CVD, highlighting the need for future 
research in this area. 
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INTRODUCTION 
  A little under two decades ago, a diagnosis of Human 
Immunodeficiency Virus (HIV)/Acquired Immunodeficiency 
Syndrome (AIDS) was viewed as a death sentence. 
Fortunately, antiretroviral therapy, specifically highly active 
antiretroviral therapy (HAART), has enabled HIV/AIDS 
patients to live longer, healthier lives [1]. With this increased 
survival, clinicians are now managing some of the 
manifestations of long-term HIV-infection. For instance, 
opportunistic infections (OIs) were once the leading cause of 
HIV/AIDS-related morbidity and mortality, but widespread 
use of HAART and OI prophylaxis has been highly effective 
in reducing the incidence of such infections [2, 3]. Presently, 
other non-AIDS-defining chronic condit-ions have emerged 
as problematic for HIV/AIDS patients. These conditions 
include renal insufficiency, hepatic disorders, metabolic 
abnormalities, and cardiovascular disease (CVD) [4-6]. 
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  CVD refers to a host of diseases and atherosclerotic 
processes that affect the cardiovascular system. The list of 
conditions that comprise this disease vary across different 
entities. For example, the American Heart Association 
(AHA) defines CVD as hypertension, coronary heart disease 
(myocardial infarction and angina pectoris), heart failure, 
stroke, or congenital cardiovascular defects [7]. The 
definition provided by the World Health Organization 
(WHO), however, is more inclusive. The WHO defines CVD 
as coronary heart disease, cerebrovascular disease, peripheral 
arterial disease, rheumatic heart disease, congenital heart 
disease, or deep vein thrombosis/pulmonary embolism [8]. 
Risk factors for developing CVD, in the absence of 
HIV/AIDS, typically include diabetes mellitus, high blood 
pressure, chronic kidney disease, obesity, tobacco use, and 
dyslipidemia [7]. 
  In addition to these traditional risk factors, Black race has 
also been postulated as a contributing factor for the 
development of CVD. Almost half of all U.S. Blacks at least 
20 years of age carry a diagnosis of CVD, whereas only one-
third of U.S. Whites in the same age group carry a CVD 
diagnosis [9]. Similar racial disparities exist in the 
HIV/AIDS population. Blacks account for almost half of all 30    The Open AIDS Journal, 2012, Volume 6  Oramasionwu et al. 
HIV/AIDS diagnoses, half of all AIDS-related deaths, and 
the majority of HIV/AIDS-related hospitalizations, despite 
accounting for only 13% of the total U.S. population [10-12]. 
Disparities for HIV/AIDS and CVD have been 
independently documented within the U.S. Black population. 
However, the development of CVD among HIV/AIDS 
Blacks has not been well characterized. Therefore, the 
present study sought to evaluate the literature regarding 
Black-White disparities for CVD in patients with HIV/AIDS 
in the United States. 
METHODS 
  A search of the electronic MEDLINE database (January 
1, 1950 to May 31, 2010) was conducted to identify relevant 
articles. The search was limited to articles published in the 
English language that evaluated CVD among patients with 
HIV/AIDS. The definition of CVD was adapted from the 
AHA definition to include heart failure, stroke, coronary 
heart disease, and hypertension. Congenital cardiovascular 
defects were not included in the present definition. A 
description of each condition is outlined in Table 1. 
  A series of initial search strategies using search terms in 
various combinations were conducted to yield the highest 
number of articles possible. The final strategy included the 
following search terms and MeSH headings: for Black race, 
“Black,” “African-American,” “race,” or “ethnicity”; for 
CVD, “cardiovascular,” “myocardial ischemia,” “heart 
failure,” “hypertension,” “cerebrovascular disorders,” or 
“stroke”; and for HIV/AIDS, “HIV,” or “AIDS.” Additional 
keywords were then added to limit the number of articles 
retrieved: “healthcare disparities,” “hospital,” 
“hospitalization,” “inpatient,” “outpatient,” or “delivery of 
health care.” Reference lists of retrieved articles were 
subsequently reviewed to identify additional, relevant 
articles. 
  Articles were included in the present review if they met 
the following criteria: 1) involved patients infected with 
HIV, 2) evaluated CVD, 3) described original research data, 
4) included only U.S. populations, 5) compared Black and 
White patients, and 6) involved non-pediatric populations. 
Articles that failed to incorporate all six of the above factors 
were excluded. The combined estimated risk for CVD 
between Blacks and Whites was not calculated due to the 
large heterogeneity in study designs, target populations, and 
endpoint definitions. 
RESULTS 
Brief Summary of the Studies 
  A total of 43 articles were identified from the literature 
search; 38 of which were excluded. Fig. (1) depicts the 
process by which articles were excluded. Of the articles 
retrieved, 13 were excluded because they did not report 
original research findings, 11 did not assess CVD, and nine 
did not evaluate HIV-infected patients. In addition, two 
articles were not U.S.-based, two articles did not evaluate 
Black-White disparities, and one article involved pediatric 
patients. 
  Only five articles met study criteria, the results of which 
are described herein. Two of the studies detected a race-
based disparity, in that HIV/AIDS Blacks were more likely 
than HIV/AIDS Whites to be diagnosed with CVD. Three 
studies did not detect such a disparity. The studies are 
summarized in Table 2 and are presented chronologically 
based on the year the study commenced. Studies that 
detected race-based disparities are discussed first. 
Table 1.  Cardiovascular Disease Definition* 
 
Cardiovascular Disease Type  Specific Conditions  ICD-9-CM Codes 
Hypertension/ 
Hypertensive Diseases 
•  Essential hypertension 
•  Hypertensive heart disease 
•  Hypertensive chronic kidney disease 
•  Hypertensive heart and chronic kidney disease 
401-404 
Coronary Heart Disease 
 
•  Acute myocardial infarction 
•  Other acute ischemic (coronary) heart disease 
•  Angina pectoris 
•  Atherosclerotic cardiovascular disease 
•  All other forms of chronic ischemic heart diseases 
410-414, 429.2 
 
Heart Failure  •  Heart failure  428 
Stroke 
 
•  Subarachnoid hemorrhage 
•  Intracerebral hemorrhage 
•  Other nontraumatic intracranial hemorrhage 
•  Cerebral infarction 
•  Stroke, not specified as hemorrhage or infarction 
•  Occlusion and stenosis of precerebral arteries not resulting in cerebral infarction 
•  Occlusion and stenosis of cerebral arteries not resulting in cerebral infarction 
•  Other cerebrovascular diseases 
•  Cerebrovascular disorders in diseases classified elsewhere 
•  Sequelae of cerebrovascular disease 
430-438 
*Adapted from the American Heart Association [7]. CVD in Blacks with HIV/AIDS  The Open AIDS Journal, 2012, Volume 6    31 
 
Studies that Detected Black-White Disparities for CVD 
among HIV/AIDS patients (n=2) 
 Gebo  et al., used a series of retrospective, cross-sectional 
analyses to document the changing patterns for inpatient 
diagnoses and causes of mortality among hospitalized HIV 
patients [13]. Hospital data from 1996, 1998, and 2000 were 
extracted from the Healthcare Costs and Utilization Project 
(HCUP) State Inpatient Database. The study included data 
from 12 of the 27 states that have participated in HCUP 
(California, Colorado, Florida, Iowa, Illinois, Kansas, 
Maryland, New Jersey, New York, Pennsylvania, South 
Carolina, and Washington). International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) codes were used to identify CVD-related 
hospitalizations. Codes 434.0–436.0 were used to denote 
cerebrovascular disease and codes 410.0–411.9 were used to 
denote ischemic heart disease. 
  In the combined three years, 316,963 HIV-related 
hospitalizations occurred. Although there was a progressive 
decrease in the number of hospitalizations from 1996 to 
 
Fig. (1). Process of article selection for the literature review. 
Articles identified from the search 
strategy (N=43) 
Remaining articles for full text review 
(N=26) 
Articles that were excluded after screening 
the abstracts (N=17) 
-No HIV (N=2) 
-No cardiovascular disease (N=2) 
-Not original research (N=10) 
-Non U.S. (N=2) 
-Non adult (N=1) 
 
 
Final articles remaining for review  
(N=5) 
Articles that were excluded after 
screening the full text (N=21) 
-No HIV (N=7) 
-No cardiovascular disease (N=9) 
-Not original research (N=3) 
-No race (N=2) 
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2000, Blacks accounted for the greatest proportion of 
hospitalizations for all years: 1996 (41%), 1998 (46%), and 
2000 (47%). Whites accounted for a decreasing proportion 
of hospitalizations: 1996 (28%), 1998 (24%), and 2000 
(23%). 
  The authors conducted several multivariable regression 
analyses in order to identify risk factors for the varying types 
of hospitalizations, including one model for ischemic heart 
disease-related hospitalizations and a separate model for 
cerebrovascular disease-related hospitalizations. All analyses 
incorporated the following covariates: race, gender, age, and 
year of hospitalization. Blacks, compared to Whites, were at 
increased risk for cerebrovascular-related hospitalizations 
(adjusted rate ratio, 1.24; 95% CI, 1.09-1.41). However, 
Blacks were found to be at decreased risk for ischemic heart 
disease-related hospitalization (adjusted rate ratio, 0.62; 95% 
CI, 0.53-0.72). These different findings suggest that there 
may be racial disparities for particular types of CVD. 
 Triant  et al., conducted a study from  1996 to 2004 to 
determine the rate of acute myocardial infarction (AMI) and 
the risk factors for developing CVD in the context of HIV 
infection [14]. The authors studied both HIV and non-HIV 
patients that received care on more than one occasion at one 
of two hospitals, Brigham and Women’s Hospital or 
Massachusetts General Hospital, both located in Boston, 
MA. Patients were identified within the Research Patient 
Data Registry, a repository of clinical and demographic data 
for both hospitals. Diagnoses of AMI were identified by 
ICD-9-CM code 410. 
Table 2.  Summary of the Five Studies that Evaluated Black-White Disparities for CVD in HIV/AIDS Patients 
 
Study  Study 
Year  Study Design  Study Setting 
N=Study 
Population, 
Race (%) 
Gender (%)  Target 
Population 
CVD 
Definition 
Risk for 
CVD/ 
Likelihood of 
CVD Event 
Studies that detected Black-White disparities for CVD among HIV/AIDS patients (n=2) 
Gebo KA 
et al. [13] 
 
1996, 
1998, 
2000 
Retrospective, 
observational 
study 
Hospital discharge 
data from the 
HCUP 
(California, 
Colorado, Florida, 
Iowa, Illinois, 
Kansas, 
Maryland, New 
Jersey, New York, 
Pennsylvania, 
South Carolina, 
Washington) 
N=316,963 
B (44%) 
W (26%) 
H (14%) 
NA/PI (1%) 
O (15%) 
M (70%) 
F (30%) 
Hospitalized 
HIV+ adults 
IHD, 
cerebrovascular 
disease 
B>W 
Triant VA 
et al. [14] 
 
1996-
2004 
Retrospective, 
observational 
study 
Registry data 
from two 
hospitals in 
Boston, MA 
N=3,851 
B (23%) 
W (54%) 
H (13%) 
A (1%) 
O (9%) 
M (70%) 
F (30%) 
 
Hospitalized 
HIV+ patients  Acute MI  B>W 
Studies that did not detect Black-Whites disparities for CVD among HIV/AIDS patients (n=3) 
Gardner LI 
et al. [15] 
1993-
2000 
Prospective, 
observational 
study 
Hospital data 
from four urban 
study sites within 
HERS (Bronx, 
NY; Detroit, MI; 
Baltimore, MD; 
Providence, RI) 
N=885 
B (61%) 
W (21%) 
H (17%) 
O (1%) 
M (0%) 
F (100%) 
Hospitalized 
HIV+ (non-
AIDS) women 
aged 16-55 
years 
Cardiomyopathy, 
IHD, CAD, MI, 
valvular defects, 
ventricular 
tachycardia, 
fibrillation, angina, 
CHF, DVT, stroke, 
TIA, CVA 
B=W 
Richter A 
et al. [16] 
1996-
2002 
Retrospective, 
observational 
study 
Database and 
medical records 
from a Southeast 
Michigan health 
system 
N=900 
B (56%) 
W (40%) 
O (4%) 
M (84%) 
F (16%) 
HIV+ adults in 
ambulatory care  Unspecified CVD  B=W 
Silverberg 
MJ et al. 
[17] 
1996-
2005 
Retrospective, 
observational 
study 
Database from 
Kaiser 
Permanente 
Northern 
California 
N=4,686 
B (20%) 
W (66%) 
H (14%) 
M (90%) 
F (10%) 
HIV+ adults 
initiated on 
antiretroviral 
therapy 
Unspecified CVD  B=W 
Acronyms: AIDS=Acquired Immunodeficiency Syndrome; CAD=Coronary artery disease; CHF=Congestive heart failure; CVA=Cerebrovascular accident; CVD=Cardiovascular 
disease; DVT=Deep vein thrombosis; HCUP=Healthcare Costs and Utilization Project; HERS=HIV Epidemiology Research Study; HIV=Human Immunodeficiency Virus; 
IHD=Ischemic heart disease; MI=Myocardial infarction; TIA=Transient ischemic attack. 
Abbreviations: Race: A=Asians; B=Blacks; W=Whites; H=Hispanics; NA=Native Americans; O=Others; PI=Pacific Islanders. 
Gender: M=Male; F=Female. CVD in Blacks with HIV/AIDS  The Open AIDS Journal, 2012, Volume 6    33 
  Only 7% of the 1,044,589 patients in the non-HIV 
infected cohort were Black, whereas, 23% of the 3,851 
patients in the HIV-positive cohort were Black. In contrast, 
66% of the non-HIV infected cohort was White and 54% of 
the HIV-positive cohort was White. There were 189 HIV-
positive patients diagnosed with an AMI; however, a racial 
distribution was not provided. The investigators performed a 
multivariable regression analysis to identify risk factors for 
diagnosis of an AMI. Their model controlled for race, HIV 
status, gender, age, and the presence of cardiac risk factors 
(diabetes, hypertension, and dyslipidemia). Black race was a 
significant predictor for AMI in the HIV group (adjusted rate 
ratio, 1.43; 95% CI, 1.01-2.00; p=0.04). This significant 
finding implies that among individuals infected with HIV, 
Blacks had a higher rate of AMI as compared to Whites. 
Studies that Did Not Detect Black-White Disparities for 
CVD among HIV/AIDS Patients (n=3) 
 The  Gardner  et al., study was the only prospective study 
identified in this review [15]. The investigators sought to 
determine the changing reasons for hospitalization for HIV 
patients from 1993-2000. The data were from the HIV 
Epidemiology Research Study (HERS), a prospective, 
multicenter, cohort study of socioeconomically 
disadvantaged women with HIV; women with a clinical 
diagnosis of AIDS at baseline were excluded. The women 
were recruited from the four study sites participating in 
HERS: Bronx, NY; Detroit, MI; Baltimore, MD; and 
Providence, RI. The investigators utilized a composite 
definition of CVD to include: “cardiomyopathy, ischemic 
heart disease, coronary artery disease, myocardial infarction, 
valvular defects, ventricular tachycardia, fibrillation, 
transient ischemic attacks, angina, congestive heart failure, 
deep vein thrombosis, and stroke or cerebrovascular 
accident” [15]. 
  There were 885 HIV-positive women included in the 
study, of which 61% were Black and 21% were White. A 
total of 2,088 hospitalizations occurred among all study 
subjects, of these, 159 were primarily related to CVD. The 
authors conducted an extensive multivariable regression 
analysis to identify independent predictors associated with 
the risk of CVD hospitalization. The model incorporated the 
following variables: age, race, alcohol use, site, development 
of clinical AIDS diagnosis, CD4+, HIV-1 RNA, HAART 
use, renal laboratory abnormalities, hypertension, hepatitis C 
virus, and injection drug use. The authors did not present the 
rate ratios for race, as the variable was not a significant 
predictor for CVD-related hospitalization per their analysis. 
Rather, progressive disease, including the development of 
AIDS and lower CD4+, were significant predictors of these 
events. 
 Richter  et al., conducted a retrospective analysis of HIV 
patients receiving outpatient care between 1996 and 2002 at 
a large health system in Southeastern Michigan [16]. The 
primary objective was to evaluate cases of dyslipidemia and 
metabolic abnormalities among patients with HIV/AIDS. 
Patient information was retrieved from an existing database 
and from patient medical records. CVD-related events were 
identified using ICD-9-CM codes; however, the exact codes 
were not listed in the study methodology. The authors 
described a validation process whereby a study investigator 
confirmed that all CVD-related events were documented in 
the patients’ medical records. Patients who lacked the 
supporting data were subsequently excluded from the CVD 
case definition. 
  Blacks comprised a little over half (56%) of the 900 
HIV-positive patients in this study and Whites accounted for 
40%. Most (61%) of the 31 CVD events occurred among 
Blacks. The absolute prevalence of CVD was similar 
between Blacks and Whites (4% vs 3%; not statistically 
significant). The investigators did not perform a 
multivariable regression analysis to investigate predictors of 
CVD-related events, nor did they comment on the CVD 
findings between Blacks and Whites, as this was not their 
primary outcome. 
 Silverberg  et al., sought to evaluate racial differences in 
antiretroviral therapy adherence rates and all-cause mortality 
in a retrospective, observational cohort study of HIV-
infected adults [17]. This was the longest study of all five, 
lasting from 1996-2005; however, this study was restricted 
to patients initiating antiretroviral therapy. The data were 
retrieved from the Kaiser Permanente Northern California 
HIV registry, an integrated managed care organization that 
maintains clinical data for over 17,000 HIV patients. While 
antiretroviral adherence was the primary study outcome, all-
cause mortality, including CVD-related mortality, was 
among the clinical endpoints that were evaluated in this 
cohort. Of the 4,686 patients included in the study, 20% 
were Black and 66% were White. There were 521 deaths 
from any cause. Of the 37 CVD-related deaths, the 
percentage was numerically greater in Blacks (9%) than in 
Whites (7%) or in Hispanics (4%). However, no bivariable 
or multivariable analyses were conducted to investigate 
possible predictors of CVD-related mortality. 
DISCUSSION 
  This is one of the first literature reviews to investigate 
racial disparities for CVD in HIV/AIDS patients. As CVD is 
a rising concern in this patient population, past studies have 
attempted to identify reasons for this epidemiologic shift. 
Possible explanations include the toxicities that are 
associated with long-term HAART exposure, the 
inflammatory effects of the virus itself, or merely the result 
of increased life expectancy [2, 18-21]. As revealed in this 
review, few studies have sought to focus on race as a 
contributing factor for CVD in HIV/AIDS patients. Although 
five articles met inclusion criteria, the diagnosis of CVD was 
only the primary outcome for three of the studies. It is, 
therefore, difficult to ascertain whether or not Blacks with 
HIV/AIDS have a higher risk for a CVD diagnosis than 
Whites with HIV/AIDS. 
  The five studies included in this review share few 
similarities. All five collected data relatively close to the 
time HAART became available in 1996; however, only the 
studies by Triant et al., study and Silverberg et al., followed 
patients for at least nine years [14, 17]. The definition of 
CVD was inconsistent ranging from unspecified case 
definitions to a host of conditions that are not typically 
classified as CVD. Three studies specified that the CVD 
diagnosis had to occur at time of hospitalization [13-15]. 
  Only two studies concluded Blacks were at increased risk 
for CVD and these were quite dissimilar in their designs [13, 34    The Open AIDS Journal, 2012, Volume 6  Oramasionwu et al. 
14]. While Gebo et al., comprised a fairly diverse study 
population with patients from 12 states, they had the shortest 
study duration with only three years of cross-sectional data 
[13]. The Triant et al., study spanned nine years, but they 
had data from only one city [14]. Interestingly, both studies 
were the only ones to provide specific definitions of CVD at 
the time of hospitalization. Both studies conducted 
regression analyses, but they only accounted for a few 
variables in their models. For instance, Gebo et al., only 
controlled for age, gender, and year and Triant et al., 
controlled for age, gender, and CVD risk factors [13, 14]. 
Neither could account for objective markers such as CD4+ 
or HIV-1 RNA. Moreover, the Gebo et al., study findings 
were actually mixed; they concluded that Blacks were at 
increased risk for cerebrovascular disease, but were actually 
at decreased risk for ischemic heart disease [13]. 
  One interpretation is that Blacks with HIV/AIDS are at 
increased risk for particular forms of CVD (i.e., AMI) as 
compared to Whites with HIV/AIDS. Alternatively, these 
mixed findings may represent racial differences in out-of-
hospital cardiac events. One limitation to the inpatient study 
setting is that analysis of hospitalized patients precludes 
evaluation of such events. As there are known regional 
variations in the incidence of out-of-hospital cardiac events 
[22], Gebo et al.’s wide geographic scope increased their 
likelihood of capturing such variations in these events, if 
they occurred. Thus, their conclusion that Blacks were at 
lower risk of ischemic heart disease-related hospitalization 
compared to Whites, could be indicative of an underlying 
problem: Blacks with HIV/AIDS with certain forms of CVD 
may be underrepresented in the inpatient setting if they 
experience these events prior to hospitalization. Such 
disparities have been noted between Blacks and Whites in 
the general U.S. population and should also be explored in 
the HIV/AIDS population [23-25]. 
  Of the studies that did not detect a disparity, Gardner et 
al., were the only investigators to prospectively address the 
issue [15]. They conducted one of the earliest studies as data 
collection ended in 2000; their results may not reflect the 
impact of newer antiretroviral therapies on the development 
of CVD. This study consisted of an all-female population 
and excluded patients with a baseline AIDS diagnosis, 
factors that may limit the generalizability of their findings. 
Due to the nature of the prospective study design, the 
investigators were able to account for several variables in 
their regression analysis, including HIV-specific data such as 
CD4+, HIV-1 RNA, and antiretroviral therapy use. Despite 
the rigorous analysis, one key limitation to this study was the 
composite definition of CVD, which included some 
conditions that are not included in the generally accepted 
definitions [7, 8]. 
  Neither of the remaining two studies performed 
regression analyses, which prevented them from identifying 
factors that may have been associated with CVD events, nor 
did they specify what conditions were classified as CVD [16, 
17]. Richter et al., only compared the prevalence of CVD 
events across the races in bivariable analyses and these 
findings were not statistically significant [16]. Blacks 
appeared underrepresented in their study, comprising only 
20% of their study population, the smallest proportion 
relative to the other studies [16]. It is important to note that 
Silverberg et al., primarily assessed medication adherence; 
their population was restricted to patients initiating 
antiretroviral therapy [17]. In addition, Silverberg et al., 
evaluated patients with equal access to care, which may have 
reduced their likelihood of detecting any disparities [17]. 
Limitations of this Literature Review 
  The findings of this review are subject to some 
methodological limitations. Every attempt was made to 
include studies that were deemed relevant, but it is likely that 
some studies were inadvertently omitted or excluded. The 
definition of CVD was defined according to the widely 
accepted definition held by the AHA. Alternative definitions 
might have changed the type of studies selected. 
Additionally, articles that assessed for surrogate markers of 
CVD were also excluded, as the intent of this review was to 
compare and contrast diagnoses of CVD in the setting of 
HIV/AIDS. Details on racial differences in traditional risk 
factors for CVD (e.g., high blood pressure, tobacco use, 
chronic kidney disease, dyslipidemia, age) were largely 
lacking from these studies. Age was not directly compared 
across the five studies as age was presented in a variety of 
formats. Future studies should address potential CVD 
disparities in aging HIV cohorts, where such events may be 
more common. Such studies should also strive to control for 
both race and HIV status. Lastly, this review only included 
full-text articles that were indexed in MEDLINE in the 
English language that were published when the review was 
conducted. Relevant studies in abstract-only format or 
indexed only in other databases would have been 
systematically excluded. The review is limited to the time 
periods that these studies were conducted (1993-2005), 
highlighting the need for up-to-date data. 
CONCLUSION 
  Blacks in the United States are increasingly at risk for 
acquiring HIV/AIDS as well as developing CVD, yet the 
evidence regarding the interaction between race, HIV/AIDS, 
and CVD is limited. Future investigations should evaluate 
racial differences in HIV/AIDS patients that develop CVD 
and differentiate between the different forms of CVD. 
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